# Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.

> **NCT07394946** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Cancer Care Hospital & Research Centre Foundation, Lahore** · enrollment: 126 (estimated)

## Conditions studied

- Hormone Receptor-Positive, HER2-Negative, Node Positive Breast Cancer

## Interventions

- **DRUG:** Letrozole

## Key facts

- **NCT ID:** NCT07394946
- **Lead sponsor:** Cancer Care Hospital & Research Centre Foundation, Lahore
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06
- **Primary completion:** 2027-07
- **Final completion:** 2029-07
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07394946

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07394946, "Neoadjuvant Letrozole in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative, Node Positive, Early-Stage Breast Cancer.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07394946. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*